Zobrazeno 1 - 10
of 173
pro vyhledávání: '"Lemström, Karl B."'
Autor:
Broch, Kaspar, Lemström, Karl B., Gustafsson, Finn, Eiskjær, Hans, Karason, Kristjan, Gjesdal, Grunde, Fagerland, Morten W., Pentikainen, Markku, Lommi, Jyri, Gude, Einar, Andreassen, Arne K., Clemmensen, Tor S., Christiansen, Evald H., Bjørkelund, Elisabeth, Berg, Erlend S., Arora, Satish, Gullestad, Lars
Publikováno v:
In JACC: Heart Failure October 2024 12(10):1677-1688
Autor:
Holmström, Emil J., Syrjälä, Simo O., Dhaygude, Kishor, Tuuminen, Raimo, Krebs, Rainer, Lommi, Jyri, Nykänen, Antti, Lemström, Karl B.
Publikováno v:
In Journal of Heart and Lung Transplantation October 2024 43(10):1677-1690
Autor:
Holmström, Emil J., Syrjälä, Simo O., Dhaygude, Kishor, Tuuminen, Raimo, Krebs, Rainer, Nykänen, Antti, Lemström, Karl B.
Publikováno v:
In Journal of Heart and Lung Transplantation June 2023 42(6):807-818
Autor:
Krebs, Rainer, Tikkanen, Jussi M., Raissadati, Alireza, Hollmén, Maria, Dhaygude, Kishor, Lemström, Karl B.
Publikováno v:
In The American Journal of Pathology February 2022 192(2):254-269
Publikováno v:
In Trends in Cardiovascular Medicine April 2013 23(3):85-90
Autor:
Lukac, Jan, Dhaygude, Kishor, Saraswat, Mayank, Joenväärä, Sakari, Syrjälä, Simo O., Holmström, Emil J., Krebs, Rainer, Renkonen, Risto, Nykänen, Antti I., Lemström, Karl B.
Publisher Copyright: © 2021 The Authors Background: The pathophysiological changes related to brain death may affect the quality of the transplanted organs and expose the recipients to risks. We probed systemic changes reflected in donor plasma prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1593::5c8cb91b01f73f014622ade0439de46d
http://hdl.handle.net/10138/341127
http://hdl.handle.net/10138/341127
Autor:
Krebs, Rainer, Tikkanen, Jussi M., Ropponen, Jussi O., Jeltsch, Michael, Jokinen, Janne J., Ylä-Herttuala, Seppo, Nykänen, Antti I., Lemström, Karl B.
Publikováno v:
In The American Journal of Pathology November 2012 181(5):1607-1620
The median survival of patients with heart transplants is relatively limited, implying one of the most relevant questions in the field-how to expand the lifespan of a heart allograft? Despite optimal transplantation conditions, we do not anticipate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1593::2c987e64f4a80122ced4cfbe86e309b0
http://hdl.handle.net/10138/338793
http://hdl.handle.net/10138/338793
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Broch, Kaspar, Gude, Einar, Karason, Kristjan, Dellgren, Göran, Rådegran, Göran, Gjesdal, Grunde, Gustafsson, Finn, Eiskjær, Hans, Lommi, Jyri, Pentikainen, Markku, Lemström, Karl B., Andreassen, Arne K., Gullestad, Lars
Publikováno v:
Broch, Kaspar Gude, Einar Karason, Kristjan Dellgren, Göran Rådegran, Göran Gjesdal, Grunde Gustafsson, Finn Eiskjær, Hans Lommi, Jyri Pentikainen, Markku Lemström, Karl B. Andreassen, Arne K. Gullestad, Lars . Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial. Clinical Transplantation. 2020, 34:e13984(9), 1-7
Clinical Transplantation
Clinical Transplantation